SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA 2004; 291: 234450.
  • 2
    Fairman KA, Motheral BR, Henderson RR. Retrospective, long-term followup study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clin Ther 2003; 25: 314761.
  • 3
    Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care 2001; 39: 1293304.
  • 4
    Motheral BR, Henderson R. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation. Am J Manag Care 1999; 5: 138394.
  • 5
    Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 2003; 349: 222432.
  • 6
    Brixner DI, Joish VN, Odera GM, Avey SG, Hanson DM, Cannon HE. Effects of benefit design change across 5 disease states. Am J Manag Care 2007; 13: 3706.
  • 7
    Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care 2005; 11: 6218.
  • 8
    Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 2007; 298: 619.
  • 9
    American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 32846.
  • 10
    Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 3545.
  • 11
    Haraoui B. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis. J Rheumatol Suppl 2005; 72: 467.
  • 12
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 158693.
  • 13
    Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 67581.
  • 14
    Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006; 54: 71622.
  • 15
    Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 304654.
  • 16
    Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in Southern Sweden. Ann Rheum Dis 2004; 63: 410.
  • 17
    Farahani P, Levine M, Gaebel K, Wang EC, Khalidi N. Community-based evaluation of etanercept in patients with rheumatoid arthritis. J Rheumatol 2006; 33: 66570.
  • 18
    Bresnihan B. Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis. Ann Rheum Dis 2002; 61 Suppl 2: ii747.
  • 19
    Paulus HE, Weaver AL, Yu EB, Woolley JM, Xia HA, Louie J. Employed rheumatoid arthritis patients experienced decreased work loss on etanercept treatment. Poster presented at the Annual European Congress of Rheumatology; 2005 June 8–11; Vienna, Austria. Vienna: EULAR; 2005.
  • 20
    Dor A, Encinosa W. Does cost sharing affect compliance? The case of prescription drugs. NBER working paper no. 10738. 2004. URL: http://papers.nber.org/papers/w10738.
  • 21
    Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff (Millwood) 2006; 25: 131931.
  • 22
    Soumerai SB, Pierre-Jacques M, Zhang F, Ross-Degnan D, Adams AS, Gurwitz J, et al. Cost-related medication nonadherence among elderly and disabled Medicare beneficiaries: a national survey 1 year before the Medicare drug benefit. Arch Intern Med 2006; 166: 182935.
  • 23
    Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S. The effects of prescription drug copayments on statin adherence. Am J Manag Care 2006; 12: 50917.
  • 24
    Ozminkowski RJ, Marder WD, Hawkins K, Wang S, Stallings SC, Finkelstein SN, et al. The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans. Clin Ther 2004; 26: 134154.
  • 25
    Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006; 40: 12808.
  • 26
    Physicians' desk reference. Montvale (NJ): Thomson Healthcare; 2004.
  • 27
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 6139.
  • 28
    Viller F, Guillemin F, Briancon S, Moum T, Suurmeijer T, van den Heuvel W. Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol 1999; 26: 211422.
  • 29
    De Klerk E, van der Heijde D, Landewe R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout [published erratum appears in J Rheumatol 2003;30:423]. J Rheumatol 2003; 30: 4454.
  • 30
    Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003; 9 Suppl 6: S13643.
  • 31
    Gilbert TD Jr, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004; 5: 36.
  • 32
    Hsu J, Price M, Huang J, Brand R, Fung V, Hui R, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med 2006; 354: 234959.